 |
BioWorld-International-2004-11-17
CAT Slowing Down Trabio Following Failed Phase II/III
CAT Slowing Down Trabio Following Failed Phase II/III
LONDON - Cambridge Antibody Technology Group plc has begun to wind down expenditure on Trabio, the first antibody it has developed in-house, after the product failed to meet its primary endpoint in a European Phase II/III pivotal trial. (BioWorld International)